Immune System

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer. 

Mymetics to manufacture HER-Vaxx cancer immunotherapy

Mymetics to manufacture HER-Vaxx cancer immunotherapy

By Zachary Brennan

Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.

EMA revises what it classifies as advanced-therapy treatments

EMA revises what it classifies as advanced-therapy treatments

By Zachary Brennan

The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs. 

Cytovance to manufacture Pamlico Biopharma antibodies

Cytovance to manufacture Pamlico Biopharma antibodies

By Zachary Brennan

CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. 

Neutrophils: Stada and Apotex to enter crowded EU filgrastim  market

update

Stada to sell Apotex' biosimilar filgrastim in Europe

By Gareth Macdonald

Stada Arzneimittel has licensed European rights to a biosimilar version of the white blood cell booster filgrastim from Apotex and says it is not worried by competitors already in the market.

New Melanoma Vaccine Tech Enters Ph I Trial

Harvard’s New Melanoma Vaccine Tech Enters Ph I Trial

By Zachary Brennan

A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.